Vicarious Surgical officially shutting down

Vicarious Surgical investors today voted to shut down and liquidate the surgical robotics developer immediately. The news was first reported by our sister website MassDevice . Vicarious CEO Stephen From, who joined the company in 2025 and lost his job today along with the other remaining Vicarious Surgical employees, said he was in talks with a potential buyer in recent days.

Instead, medical device OEMs have signed non-disclosure agreements to access the company’s data room while Vicarious Surgical assets are auctioned off .

“I was so impressed with what they were able to do,” From told MassDevice . “That’s why I’m so mad. I’m so frustrated. This is the type of platform that deserves to be in the clinic and in the hospitals, helping patients. That’s a shame.”

The company raised about $300 million in total — most of that from a special purpose acquisition company (SPAC) merger in 2021 — but could not get its R&D program to a design freeze, which From hoped to achieve by the end of 2026.

The company was spending about $50 million year when From joined the company in August 2025, he said, and restructuring got the burn rate below $20 million by the beginning of this year without pushing back the end-of-2026 design freeze target.

But by then the company’s market capitalization had dropped enough that the NYSE put Vicarious Surgical on its watch list for potential delisting, and that killed the company’s efforts to raise more cash.

“We got this notification, and the bankers, rightly so, said it’s over,” From said. “… With the money we had in the bank when we went out in January, we said another $10 million net would get us to the end of the year.”

The Vicarious Surgical board unanimously proposed the closure and liquidation , saying it could not predict whether there would be anything left to repay investors. An assignee will liquidate the soft-tissue robotics developer’s assets to settle outstanding obligations.

“Since inception, we have experienced recurring operating losses and negative cash flows, and we expect to continue to generate operating losses and consume significant cash resources for the foreseeable future,” the company said ahead of today’s special meeting of stockholders, reporting nearly $3.7 million of cash, cash equivalents and short-term investments as of March 31.

“We do not expect our cash and cash equivalents to be sufficient to continue as a going concern for any significant period of time,” the company continued. “Although we are currently exploring various strategic alternatives, including strategic partners and financing opportunities, it is unlikely that these strategic alternatives will be successful in the next few weeks prior to our cash position getting to the point that we will need to pursue our winding down and dissolution. To date, we have been unable to secure additional equity, debt or other financing and have been unsuccessful in our efforts to attract a buyer for our business.”